Market Research Logo

Melanoma - Pipeline Review, H1 2015

Melanoma - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Melanoma - Pipeline Review, H1 2015’, provides an overview of the Melanoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Melanoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Melanoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Melanoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Melanoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Melanoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Melanoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Melanoma Overview
Therapeutics Development
Melanoma – Therapeutics under Development by Companies
Melanoma – Therapeutics under Investigation by Universities/Institutes
Melanoma – Pipeline Products Glance
Melanoma – Products under Development by Companies
Melanoma – Products under Investigation by Universities/Institutes
Melanoma – Companies Involved in Therapeutics Development
Melanoma – Therapeutics Assessment
Drug Profiles
Melanoma – Recent Pipeline Updates
Melanoma – Dormant Projects
Melanoma – Discontinued Products
Melanoma – Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Melanoma, H1 2015
Number of Products under Development for Melanoma – Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Development by Companies, H1 2015 (Contd..4)
Number of Products under Development by Companies, H1 2015 (Contd..5)
Number of Products under Development by Companies, H1 2015 (Contd..6)
Number of Products under Development by Companies, H1 2015 (Contd..7)
Number of Products under Development by Companies, H1 2015 (Contd..8)
Number of Products under Development by Companies, H1 2015 (Contd..9)
Number of Products under Development by Companies, H1 2015 (Contd..10)
Number of Products under Development by Companies, H1 2015 (Contd..11)
Number of Products under Development by Companies, H1 2015 (Contd..12)
Number of Products under Development by Companies, H1 2015 (Contd..13)
Number of Products under Development by Companies, H1 2015 (Contd..14)
Number of Products under Development by Companies, H1 2015 (Contd..15)
Number of Products under Development by Companies, H1 2015 (Contd..16)
Number of Products under Development by Companies, H1 2015 (Contd..17)
Number of Products under Investigation by Universities/Institutes, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..4)
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Development by Companies, H1 2015 (Contd..5)
Products under Development by Companies, H1 2015 (Contd..6)
Products under Development by Companies, H1 2015 (Contd..7)
Products under Development by Companies, H1 2015 (Contd..8)
Products under Development by Companies, H1 2015 (Contd..9)
Products under Development by Companies, H1 2015 (Contd..10)
Products under Development by Companies, H1 2015 (Contd..11)
Products under Development by Companies, H1 2015 (Contd..12)
Products under Development by Companies, H1 2015 (Contd..13)
Products under Development by Companies, H1 2015 (Contd..14)
Products under Development by Companies, H1 2015 (Contd..15)
Products under Development by Companies, H1 2015 (Contd..16)
Products under Development by Companies, H1 2015 (Contd..17)
Products under Development by Companies, H1 2015 (Contd..18)
Products under Development by Companies, H1 2015 (Contd..19)
Products under Development by Companies, H1 2015 (Contd..20)
Products under Development by Companies, H1 2015 (Contd..21)
Products under Development by Companies, H1 2015 (Contd..22)
Products under Development by Companies, H1 2015 (Contd..23)
Products under Development by Companies, H1 2015 (Contd..24)
Products under Development by Companies, H1 2015 (Contd..25)
Products under Investigation by Universities/Institutes, H1 2015
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..5)
Melanoma – Pipeline by 4SC AG, H1 2015
Melanoma – Pipeline by AB Science, H1 2015
Melanoma – Pipeline by AbbVie Inc., H1 2015
Melanoma – Pipeline by Adamis Pharmaceuticals Corporation, H1 2015
Melanoma – Pipeline by Adaptimmune Limited, H1 2015
Melanoma – Pipeline by Aduro BioTech, Inc., H1 2015
Melanoma – Pipeline by Advaxis, Inc., H1 2015
Melanoma – Pipeline by Aeterna Zentaris Inc., H1 2015
Melanoma – Pipeline by Affichem, H1 2015
Melanoma – Pipeline by Agalimmune Ltd, H1 2015
Melanoma – Pipeline by Agenus, Inc., H1 2015
Melanoma – Pipeline by AGV Discovery, SAS, H1 2015
Melanoma – Pipeline by AIMM Therapeutics B.V., H1 2015
Melanoma – Pipeline by Alethia Biotherapeutics Inc., H1 2015
Melanoma – Pipeline by Altor BioScience Corporation, H1 2015
Melanoma – Pipeline by Amgen Inc., H1 2015
Melanoma – Pipeline by Amorfix Life Sciences Ltd., H1 2015
Melanoma – Pipeline by Anavex Life Sciences Corp., H1 2015
Melanoma – Pipeline by Antigen Express, Inc., H1 2015
Melanoma – Pipeline by APEIRON Biologics AG, H1 2015
Melanoma – Pipeline by Aphios Corporation, H1 2015
Melanoma – Pipeline by APO-T B.V., H1 2015
Melanoma – Pipeline by Aposense Ltd., H1 2015
Melanoma – Pipeline by Applied Immune Technologies Ltd, H1 2015
Melanoma – Pipeline by Aptose Biosciences Inc., H1 2015
Melanoma – Pipeline by Arisaph Pharmaceuticals, Inc., H1 2015
Melanoma – Pipeline by Array BioPharma Inc., H1 2015
Melanoma – Pipeline by Arrowhead Research Corporation, H1 2015
Melanoma – Pipeline by Astex Pharmaceuticals, Inc., H1 2015
Melanoma – Pipeline by AstraZeneca Plc, H1 2015
Melanoma – Pipeline by Aura Biosciences, Inc., H1 2015
Melanoma – Pipeline by Aurigene Discovery Technologies Limited, H1 2015
Melanoma – Pipeline by AVAX Technologies, Inc., H1 2015
Melanoma – Pipeline by Axelar AB, H1 2015
Melanoma – Pipeline by Azaya Therapeutics Incorporated, H1 2015
Melanoma – Pipeline by Basilea Pharmaceutica AG, H1 2015
Melanoma – Pipeline by Bayer AG, H1 2015
Melanoma – Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015
Melanoma – Pipeline by Bio-Cancer Treatment International Limited, H1 2015
Melanoma – Pipeline by Biogenomics Limited, H1 2015
Melanoma – Pipeline by BioLineRx, Ltd., H1 2015
Melanoma – Pipeline by Bioncotech Therapeutics S.L., H1 2015
Melanoma – Pipeline by Bionomics Limited, H1 2015
Melanoma – Pipeline by BioNTech AG, H1 2015
Melanoma – Pipeline by Bioo Therapeutics, H1 2015
Melanoma – Pipeline by Biovista Inc., H1 2015
Melanoma – Pipeline by Boehringer Ingelheim GmbH, H1 2015
Melanoma – Pipeline by Boston Biomedical, Inc., H1 2015
Melanoma – Pipeline by Bristol-Myers Squibb Company, H1 2015
Melanoma – Pipeline by Caladrius Biosciences, Inc. , H1 2015
Melanoma – Pipeline by Cantargia AB, H1 2015
Melanoma – Pipeline by cCAM Biotherapeutics Ltd., H1 2015
Melanoma – Pipeline by CCRP Therapeutics GmbH, H1 2015
Melanoma – Pipeline by Celgene Corporation, H1 2015
Melanoma – Pipeline by Celldex Therapeutics, Inc., H1 2015
Melanoma – Pipeline by Celyad, H1 2015
Melanoma – Pipeline by Champions Oncology, Inc., H1 2015
Melanoma – Pipeline by Cipher Pharmaceuticals Inc., H1 2015
Melanoma – Pipeline by Conkwest, Inc., H1 2015
Melanoma – Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015
Melanoma – Pipeline by CSL Limited, H1 2015
Melanoma – Pipeline by CureFAKtor Pharmaceuticals, LLC, H1 2015
Melanoma – Pipeline by CureTech Ltd., H1 2015
Melanoma – Pipeline by Cytune Pharma SAS, H1 2015
Melanoma – Pipeline by CZ BioMed Corp, H1 2015
Melanoma – Pipeline by Daiichi Sankyo Company, Limited, H1 2015
Melanoma – Pipeline by Deciphera Pharmaceuticals, LLC, H1 2015
Melanoma – Pipeline by Delcath Systems, Inc., H1 2015
Melanoma – Pipeline by DermaXon, LLC, H1 2015
Melanoma – Pipeline by Dicerna Pharmaceuticals, Inc., H1 2015
Melanoma – Pipeline by Digna Biotech, S.L., H1 2015
Melanoma – Pipeline by DNA Therapeutics S.A., H1 2015
Melanoma – Pipeline by DormaTarg, Inc., H1 2015
Melanoma – Pipeline by EcoBiotics Limited, H1 2015
Melanoma – Pipeline by Egenix, Inc., H1 2015
Melanoma – Pipeline by Eisai Co., Ltd., H1 2015
Melanoma – Pipeline by Eli Lilly and Company, H1 2015
Melanoma – Pipeline by EntreChem, S.L., H1 2015
Melanoma – Pipeline by Erytech Pharma SA, H1 2015
Melanoma – Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Melanoma – Pipeline by FirstString Research, Inc., H1 2015
Melanoma – Pipeline by Formune S.L., H1 2015
Melanoma – Pipeline by Galapagos NV, H1 2015
Melanoma – Pipeline by Galectin Therapeutics, Inc., H1 2015
Melanoma – Pipeline by Galileo Research s.r.l., H1 2015
Melanoma – Pipeline by Genelux Corporation, H1 2015
Melanoma – Pipeline by Genticel S.A., H1 2015
Melanoma – Pipeline by Genzyme Corporation, H1 2015
Melanoma – Pipeline by GlaxoSmithKline Plc, H1 2015
Melanoma – Pipeline by Gradalis Inc., H1 2015
Melanoma – Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2015
Melanoma – Pipeline by HanAll Biopharma Co., Ltd., H1 2015
Melanoma – Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015
Melanoma – Pipeline by Hemispherx Biopharma, Inc., H1 2015
Melanoma – Pipeline by Histogen, Inc., H1 2015
Melanoma – Pipeline by Ignyta, Inc., H1 2015
Melanoma – Pipeline by Immodulon Therapeutics Ltd., H1 2015
Melanoma – Pipeline by Immune Design Corp., H1 2015
Melanoma – Pipeline by Immune Response BioPharma, Inc., H1 2015
Melanoma – Pipeline by ImmunGene, Inc., H1 2015
Melanoma – Pipeline by ImmunNovative Developments SL, H1 2015
Melanoma – Pipeline by Immunocore Limited, H1 2015
Melanoma – Pipeline by ImmunoFrontier, Inc., H1 2015
Melanoma – Pipeline by ImmunoGen, Inc., H1 2015
Melanoma – Pipeline by Immunomic Therapeutics, Inc., H1 2015
Melanoma – Pipeline by Immunophotonics Inc, H1 2015
Melanoma – Pipeline by ImmuRx, Inc., H1 2015
Melanoma – Pipeline by IMPACT Therapeutics, Inc., H1 2015
Melanoma – Pipeline by Imugene Limited, H1 2015
Melanoma – Pipeline by Incyte Corporation, H1 2015
Melanoma – Pipeline by Inovio Pharmaceuticals, Inc., H1 2015
Melanoma – Pipeline by InteRNA Technologies B.V., H1 2015
Melanoma – Pipeline by ISA Pharmaceuticals B.V., H1 2015
Melanoma – Pipeline by Kadmon Corporation, LLC, H1 2015
Melanoma – Pipeline by KAEL-GemVax Co., Ltd., H1 2015
Melanoma – Pipeline by Karyopharm Therapeutics, Inc., H1 2015
Melanoma – Pipeline by Laboratoires Pierre Fabre SA, H1 2015
Melanoma – Pipeline by Lentigen Technology, Inc., H1 2015
Melanoma – Pipeline by Life Science Pharmaceuticals, Incorporated, H1 2015
Melanoma – Pipeline by Lindis Biotech GmbH, H1 2015
Melanoma – Pipeline by Lipotek Pty Ltd., H1 2015
Melanoma – Pipeline by Luitpold Pharmaceuticals, Inc., H1 2015
Melanoma – Pipeline by Lytix Biopharma AS, H1 2015
Melanoma – Pipeline by MacroGenics, Inc., H1 2015
Melanoma – Pipeline by Magnus Life Science, H1 2015
Melanoma – Pipeline by MediaPharma s.r.l., H1 2015
Melanoma – Pipeline by MedImmune, LLC, H1 2015
Melanoma – Pipeline by Merck & Co., Inc., H1 2015
Melanoma – Pipeline by Merck KGaA, H1 2015
Melanoma – Pipeline by Millennium Pharmaceuticals, Inc., H1 2015
Melanoma – Pipeline by Mologen AG, H1 2015
Melanoma – Pipeline by Momenta Pharmaceuticals, Inc., H1 2015
Melanoma – Pipeline by Morphotek, Inc., H1 2015
List of Figures
Number of Products under Development for Melanoma, H1 2015
Number of Products under Development for Melanoma – Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report